Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

FromShort Wave


FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

FromShort Wave

ratings:
Length:
12 minutes
Released:
Jun 25, 2021
Format:
Podcast episode

Description

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."You can email Short Wave at ShortWave@NPR.org.
Released:
Jun 25, 2021
Format:
Podcast episode

Titles in the series (100)

New discoveries, everyday mysteries, and the science behind the headlines — all in about 10 minutes, every weekday. It's science for everyone, using a lot of creativity and a little humor. Join host Maddie Sofia for science on a different wavelength.